TAKARA BIO INC.
タカラバイオ株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4974
FY2024 (Mar 2025) · J-GAAP · consolidated Source: filing S100VZNP
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2024 (Mar 2025) runs Apr 1, 2024 – Mar 31, 2025.
| Gross margin | 57.9% |
|---|---|
| Operating margin | 5.0% |
| Net margin | 2.3% |
| Return on equity | 0.9%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 0.8% |
| Revenue growth (YoY) | 3.5% |
| EPS (basic) | ¥8.65 |
| EPS growth (YoY) | -29.7% |
| Current ratio | 8.09x |
| Equity ratio | 92.2% |
| Book value / share | ¥959.19 |
| Free cash flow | −¥4.0B |